Company: IMNN
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001641172-25-009572
Chunk: 121

Company: Imunon, Inc.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 8
Chunk 121
---
ability and classification of assets, carrying amounts or the amount and classification
of liabilities that may be required should the Company be unable to continue as a going concern.

As
a result of the risks and uncertainties discussed in the 2024 Annual Report filed on February 27, 2025 with the SEC, among others, we are unable to estimate the duration
and completion costs of our research and development projects or when, if ever, and to what extent we will receive cash inflows from
the commercialization and sale of a product if one of our drug candidates receives regulatory approval for marketing, if at all. Our
inability to complete any of our research and development activities, preclinical studies or clinical trials in a timely manner or
our failure to enter into collaborative agreements when appropriate could significantly increase our capital requirements and could
adversely impact our liquidity. While our estimated future capital requirements are uncertain and could increase or decrease as a
result of many factors, including the extent to which we choose to advance our research and development activities, preclinical
studies and clinical trials, or whether we are in a position to pursue manufacturing or commercialization activities, we will need
significant additional capital to progress our drug candidates through development and clinical trials, obtain regulatory approvals
and manufacture and commercialize approved products, if any. We do not know whether we will be able to access additional capital
when needed or on terms favorable to us or our stockholders. Our inability to raise additional capital, or to do so on terms
reasonably acceptable to us, would jeopardize the future success of our business.

Financing
Overview

Equity,
Debt and Other Forms of Financing

During
2025 and 2024 through the date of this Quarterly Report on Form 10-Q, we issued a total of 5.2 million shares of common stock as discussed
below for approximately $9.2 million in net proceeds.

23

On
May 15, 2024, the Company filed with the SEC a shelf registration statement on Form S-3 (the “2024 Registration Statement”)
for the offer and sale of up to $75 million of its securities. The 2024 Registration Statement was declared effective on May 22, 2024.
The 2024 Registration Statement is intended to provide the Company with flexibility to raise capital in the future for general corporate
purposes. However, the Company’s ability to offer and sell its securities in a primary offering on the 2024 Registration Statement
is